Lipid profile, the world needs to change

Journal of Clinical Lipidology

Volumn 11, Issue 3, 2017, Pages 769-770

  Ferreira, Carlos Eduardo dos Santos ^a   Scartezini, Marileia ^b   França, Carolina N ^c  

^a HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^b FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^c Santo Amaro University   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; VERY LOW DENSITY LIPOPROTEIN; LIPID;

CHOLESTEROL BLOOD LEVEL; LETTER; LIPID ANALYSIS; PRIORITY JOURNAL; BLOOD; BLOOD ANALYSIS; DIET RESTRICTION; HUMAN; PROCEDURES; RISK FACTOR;

BLOOD CHEMICAL ANALYSIS; FASTING; HUMANS; LIPIDS; RISK FACTORS;

EID: 85014478885     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2017.01.019     Document Type: Letter

References (12)

1. 1 Friedewald, W.T., Lavy, R.I., Fredrickson, D.S., Estimation to density lipoprotein without use of the preparative ultracentrifuge. Clin Chem 18 (1972), 499–502.
2. 2 Martin, S.S., Blaha, M.J., Elshazly, M.B., et al. Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile. JAMA 310:19 (2013), 2061–2068.
3. 3 Scharnagl, H., Nauck, M., Wieland, H., Marz, W., The Friedewald formula underestimates LDL cholesterol at low concentrations. Clin Chem Lab Med 39 (2001), 426–431.
4. 4 Rifai, N., Young, I.S., Nordestgaard, B.G., et al. Nonfasting sample for the determination of routine lipid profile: is it an idea whose time has come?. Clin Chem 62:3 (2016), 428–435.
5. 5 Parks, E.J., McCrory, M.A., When to eat and how often?. Am J Clin Nutr 81:1 (2005), 3–4.
6. 6 Langsted, A., Freiberg, J.J., Nordestgaard, B.G., Fasting and nonfasting lipid levels: influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction. Circulation 118 (2008), 2047–2056.
7. 7 Yusuf, S., Hawkew, S., Ôunpuu, S., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 304 (2004), 937–952.
8. 8 Nordestgaard, B.G., Varbo, A., Triglycerides and cardiovascular disease. Lancet 384 (2014), 626–635.
9. 9 Nordestgaard, B.G., Langsted, A., Mora, S., et al. Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points—a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. Eur Heart J 37:25 (2016), 1944–1958.
10. 10 Sondermeijer, B.M., Rana, J.S., Arsenault, B.J., et al. Non-HDL cholesterol vs. Apo B for risk of coronary heart disease in healthy individuals: the EPIC-Norfolk prospective population study. Eur J Clin Invest 43:10 (2013), 1009–1015.
11. 11 Amor, A.J., Catalan, M., Pérez, A., et al. Nuclear magnetic resonance lipoprotein abnormalities in newly-diagnosed type 2 diabetes and their association with preclinical carotid atherosclerosis. Atherosclerosis 247 (2016), 161–169.
12. 12 Scartezini, M., Ferreira, C.E.S., Izar, M.C.O., et al. Posicionamento sobre a flexibilização do jejum para o perfil lipídico. Arq Bras Cardiol, 2017 [Epub ahead of print].